Mesa Laboratories, Inc. reported a revenue increase of 11.5% for the fiscal year ending March 31, 2025, reaching $240.98 million compared to $216.19 million in the previous year. The company achieved a gross profit of $150.87 million, reflecting a 13.2% rise from $133.25 million in fiscal year 2024. Despite this growth, Mesa recorded a net loss of $1.97 million, a significant improvement from a net loss of $254.25 million in the prior year, which had been impacted by substantial impairment losses.
The company’s financial performance was bolstered by the acquisition of GKE GmbH and SAL GmbH, which contributed $24.8 million in revenue for the fiscal year 2025. Organic revenue growth was driven primarily by the Biopharmaceutical Development division, which saw a 19.7% increase, alongside an 8.3% rise in Calibration Solutions and a 4.7% increase in Sterilization and Disinfection Control. However, the Clinical Genomics division faced challenges, experiencing a 10.5% decline in organic revenues due to regulatory changes affecting lab-developed tests.
Operationally, Mesa Laboratories maintained a workforce of 730 employees as of March 31, 2025, with a focus on improving employee engagement and reducing turnover. The company reported a backlog of approximately $43.2 million, up from $25.5 million the previous year, indicating strong demand for its products and services. The increase in backlog was attributed to timing in order placements, particularly in the Clinical Genomics and Sterilization and Disinfection Control divisions.
Looking ahead, Mesa Laboratories anticipates continued growth driven by its strategic focus on expanding its product offerings and geographic reach, particularly in the life sciences tools and quality control solutions markets. The company is also working to obtain regulatory clearance for certain GKE products in the U.S., which could further enhance revenue opportunities. However, the ongoing impact of tariffs and foreign currency fluctuations remains a concern, as these factors could affect pricing and profitability in international markets.
About MESA LABORATORIES INC /CO/
About 10-K Filings
A 10-K form is a comprehensive annual report that public companies in the United States must file with the SEC, providing a detailed overview of the company's financial condition, performance, and business strategies.
Key points about the 10-K:
- Frequency: Filed annually, typically within 60 to 90 days after the end of the company's fiscal year.
-
Content: It includes:
- Detailed financial statements audited by an independent accounting firm
- Management's Discussion and Analysis (MD&A) of financial condition and results
- Description of the company's business, properties, and legal proceedings
- Risk factors and market risks
- Executive compensation and corporate governance information
- Importance: Considered the most comprehensive and important document a public company files with the SEC.
- Length: Often exceeds 100 pages due to its extensive and detailed nature.
Our Methodology
AssetRoom is committed to providing timely summaries of news from public companies. We use AI to generate these summaries quickly, but they are not reviewed by human experts.
Our method:
- Data Collection: We continuously monitor for new filings (currently limited to US-listed stocks).
- AI-Powered Analysis: Our advanced AI system processes each filing, identifying key information and extracting relevant data.
- Summary Generation: The AI creates a concise, easy-to-understand summary of the filing, highlighting the most important points.
- Publication: The summary is immediately published on our platform, allowing users instant access to the latest information.
- Email users: We distribute round-up emails according to our users preferences, keeping them in the loop with the companies they follow.
Feedback & Corrections
Spot an error or have a suggestion? Contact us.